Efficacy comparision of bupivacain vs ropivacain in midpoint transverse process to pleura block in modified radical mastectomy surgeries

Comparison of analgesic efficacy of Bupivacain and Ropivacain in Midpoint Transverse process to pleura block for Modified Radical Mastectomy - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087076

Enrollment

128

Registered

2025-05-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Midpoint transverse process to pleura block in MRM Surgeries: 0.5% Ropivacaine or 0.25% Bupivacaine, 10ml deposited above costo transverse ligament at each T2,T3 and T5 level , preinduc

Eligibility

Inclusion criteria

Inclusion criteria: ASA Grade 1 and 2 patients scheduled for elective MRM surgeries

Exclusion criteria

Exclusion criteria: Patient refusal Patient with COPD and lung disease Patient with severe liver disease Obesity with BMI more than 31 Patient on any analgesics Local site infections Local injury Allergic to study drugs

Design outcomes

Primary

Measure	Time frame
Post surgical analgesia using VAS score,as first rescue analgesic requirements.Timepoint: Post surgical analgesia using VAS score at 0,2,4,8,10,12,16,20,24 and 48 hours, with Blood pressure, Heart rate, and SpO2 saturation	—

Secondary

Measure	Time frame
Patient satisfaction evaluated using, Likert scaleTimepoint: Liberty scale at 0,4,8,12,24 and 48 hours	—

Countries

India

Contacts

Public ContactDr Himanshu Dubey

Pt JNM Medical College Raipur CG

jayalalwani2020@gmail.com9300224989

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026